HIV-fertőzés: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CCR5 1
• CXCR4 0
• PD-1 2
• IL-15 1
• JAK 1
• STING 0
• GLP-1 2
• IL-17 0
• PD-L1 1
• TNF 0
• IL-6 0
• mTOR 1
• TP53 0
• NLRP3 0
• SGLT2 2
• STAT3 0
• AKT 0
• APOL1 0
• PCSK9 0
• PPAR 0
• CD40 1
• NRF2 0
• PI3K 0
• BCL-2 2
• CD19 1
• ERK 0
• HDAC 0
• HIF-1 0
• APOE 0
• BRD4 0
• FOXP3 0
• HSP90 0
• MAPK 0
• METTL3 0
• AMPK 0
• ATM 0
• BDNF 0
• CD20 0
• CD38 0
• CTNNB1 0
• FLT3 0
• HMGB1 0
• IL-1 0
• MET 0
• NMDA 0
• TIGIT 0
• VEGF 0
• ACE2 0
• ALK 0
• ANGPTL3 0
• AQP4 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CFTR 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Comparative and entangled histories of AIDS care in Austria and Slovenia, 1980s–2000s (AIDScare)

  Universitaet Graz· Graz, Ausztria· EU contribution 230 185 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Immunometabolic Reprogramming via a Gut-derived Organoid Platform (IRGOP)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  BRIDGING RESERVOIR SCIENCE, INTEGRATED DRUG DISCOVERY, BIG DATA ANALYTICS, ARTIFICIAL INTELLIGENCE AND EPIDEMIOLOGY (BRIDGE-HIV)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 1 703 400 EUR· until 2030. szept.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Hollandia· EU contribution 12 751 885 EUR· until 2031. jún.· 14 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the Landscape of Transcriptional Activity during HIV-1 Infection (DELTA-HIV)

  King's College London· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. máj.

5 of 25 running projects, newest first. Listed amounts together: 81,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 22
• Organoids 6
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 27
• Gene Expression Profiling 62
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 15
• Exome Sequencing 3
• Proteomics 37
• Metabolomics 33
• Mass Spectrometry 16
• Flow Cytometry 45
• Immunohistochemistry 15
• Xenograft Model Antitumor Assays 3
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 79
• Machine Learning 71
• Deep Learning 21
• Cohort Studies 426
• Genome-Wide Association Study 20

• Emergency Department Management of Body-Fluid Exposures Receiving Human Immunodeficiency Virus Post-Exposure Prophylaxis: Adherence to Australian Guideline Recommendations.

  Emerg Med Australas, 2026. dec.

• Weight Trajectories in Virally Suppressed People With HIV Compared With Matched People Without HIV, and Predictors of Weight Gain: A 3-Year Cohort Study From the US TRIO Healthcare Network.

  J Acquir Immune Defic Syndr, 2026. nov.

• Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China.

  Liver Int, 2026. nov.

• Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, by Chronic Liver Disease Status.

  J Acquir Immune Defic Syndr, 2026. nov.

• Prevalence and Predictors of Abnormal Cervical Cytology Among Women Living With HIV and Without HIV From the MACS/WIHS Combined Cohort Study.

  J Acquir Immune Defic Syndr, 2026. nov.

• Comorbidity burden and outcomes with long-acting cabotegravir plus rilpivirine in the RELATIVITY cohort.

  AIDS, 2026. okt.

• Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort.

  Clin Infect Dis, 2026. okt.

• Multimorbidity Trajectories and Hospitalization Risk Among People With HIV in Sub-Saharan Africa: A Longitudinal Analysis From the African Cohort Study.

  Clin Infect Dis, 2026. okt.

• Associations between biomarkers and clinical outcome in people hospitalized with HIV: a retrospective cohort.

  Rev Lat Am Enfermagem, 2026. okt.

• Understanding viral blips in people with HIV on antiretroviral therapy: a nationwide Swedish cohort study of 4,210 individuals.

  BMC Infect Dis, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.